Second-line therapy adjustment for advanced pancreatic cancer using circulating tumor cells: Preliminary results
The preliminary results indicate that 2L treatment based on CTCs' response in vitro prolongs MS of APC patients compared with 2L-BSC-treated ones, potentially leading to the development of more effective 2L APC therapy plans.
Authors
- Hüseyin Sahinbas
- Panagiotis Apostolou (ORCID: https://orcid.org/0000-0001-6564-1114)
- Ioannis Papasotiriou (ORCID: https://orcid.org/0000-0002-6145-946X)
- Mandeep Singh Malhotra
- George Beis
- Aggelos Iliopoulos
- Joachim Drevs
Institutions
- Bir Hospital (NP)
- University Medical Center Freiburg (DE)
- Materials Industrial Research and Technology Development Centre (Greece) (GR)
- Orthopädische Praxis (DE)
- International Breast Cancer Study Group (CH)
Publication Details
- Journal
- Cancer Treatment and Research Communications
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ctarc.2025.100956
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00